RxDoctor Payments Data

Yu-Ping Wang

Cardiovascular Disease · Stanford, CANPI 1275717761

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $59,953 of the $79,127 with a category attached, or 75.8%. 9 manufacturers reported payments, led by AstraZeneca at 26.7% of the total. Reporting peaked in 2021 at $29,720 and has fallen 99.7% since, to $77 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,127in general payments, 2019–2025

Across 62 payments — averaging $1276.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$21K
  • Artivion, Inc.$20K
  • Novartis$18K
  • CSL Behring$10K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Bio Products Laboratory USA, Inc.$3K
  • plus $2K from 3 others
$3,702,748in research payments, 2019–2025

Across 24 payments — averaging $154,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Artivion, Inc.$3.2M
  • AstraZeneca$295K
  • Regeneron$162K
  • Boston Scientific$44K
  • Novo Nordisk AS$11K

What the payments were for

  • Consulting fees$59,95376%
  • Speaking & faculty fees$14,44118%
  • Travel & lodging$3,4944%
  • Food & beverage$1,1441%
  • Education$950%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca20$21,162
Artivion, Inc.18$19,621
Novartis7$17,717
CSL Behring3$10,435
E.r. Squibb & Sons, L.L.C.4$5,273
Bio Products Laboratory USA, Inc.2$2,750
Regeneron3$1,878
Johnson & Johnson(2 entities)2$214
LEO Pharma Inc.3$77

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,127 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in Stanford

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →